Genomics and Precision Medicine to Combat Opioid Use Disorder - 30/03/19

| Funding: This research was supported in part by NIH ROI DA044015. JR, JC, and CHH are funded by the Charles E. Schmidt College of Medicine of Florida Atlantic University. JR is also funded by a multi-investigator-initiated research grant from the National Institutes of Health (R01 DA044015) to identify clinical and genetic predictors of opioid use disorder in a large population. |
|
| Conflict of Interest: CHH serves as an independent scientist in an advisory role to investigators and sponsors as chair or member of data and safety monitoring boards for Amgen, British Heart Foundation, Cadila, Canadian Institutes of Health Research, DalCor, Regeneron, and the Wellcome Foundation, as well as to the US Food and Drug Administration, and UpToDate; receives royalties for authorship or editorship of 3 textbooks and as co-inventor on patents for inflammatory markers and cardiovascular disease that are held by Brigham and Women's Hospital; and has an investment management relationship with the West-Bacon Group within SunTrust Investment Services, which has discretionary investment authority and does not own any common or preferred stock in any pharmaceutical or medical device company. |
|
| Authorship: All authors had access to the data and a role in writing this manuscript. |
Vol 132 - N° 4
P. 395-396 - avril 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
